Solid Biosciences (NASDAQ:SLDB) Shares Up 5.5% After Analyst Upgrade

Solid Biosciences Inc. (NASDAQ:SLDB) shares traded up 5.5% during trading on Thursday after Truist Financial upgraded the stock to a strong-buy rating. The company traded as high as $7.61 and last traded at $7.63. 335,353 shares were traded during mid-day trading, a decline of 75% from the average session volume of 1,345,952 shares. The stock had previously closed at $7.23.

Several other equities analysts have also commented on SLDB. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Solid Biosciences in a research note on Friday, March 20th. Guggenheim started coverage on shares of Solid Biosciences in a research report on Friday, March 20th. They issued a “buy” rating and a $26.00 target price on the stock. Chardan Capital reiterated a “buy” rating and set a $15.00 price target on shares of Solid Biosciences in a research report on Friday, March 20th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Solid Biosciences in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.09.

Insider Activity at Solid Biosciences

In related news, insider Gabriel Brooks sold 28,335 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $6.44, for a total transaction of $182,477.40. Following the completion of the transaction, the insider directly owned 96,708 shares in the company, valued at $622,799.52. This trade represents a 22.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jessie Hanrahan sold 26,535 shares of Solid Biosciences stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $6.44, for a total value of $170,885.40. Following the completion of the transaction, the insider directly owned 82,675 shares of the company’s stock, valued at approximately $532,427. This represents a 24.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 597,672 shares of company stock worth $3,816,546 over the last ninety days. Company insiders own 1.90% of the company’s stock.

Key Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Truist upgraded SLDB to “Strong‑Buy” on 3/26, signaling increased conviction from another sell‑side shop; this upgrade likely supported buying interest. Zacks Article
• Positive Sentiment: JPMorgan raised its price target from $11 to $12 and kept an “Overweight” rating (3/25). The new target implies roughly ~58% upside from the referenced $7.61 price, providing a clear catalyst for upside re‑rating. Benzinga Article
• Positive Sentiment: HC Wainwright reiterated a “Buy” and a $20 target while materially raising near‑term EPS forecasts (e.g., Q1 2026 EPS revised from ($0.52) to ($0.35); FY2026 from ($2.12) to ($1.43)) and publishing a multi‑year path to profitability (FY2029 $0.89; FY2030 $1.81). The upgrades to estimates and the high $20 target are significant bullish signals for sentiment and valuation. American Banking News Article
• Neutral Sentiment: Data providers reported a “large increase” in short interest for March but the published figures show 0 shares and NaN changes — this appears to be a reporting/error issue and is not a reliable signal. Investors should treat short‑interest headlines cautiously until corrected filings are available.

Institutional Investors Weigh In On Solid Biosciences

Several large investors have recently added to or reduced their stakes in the business. MetLife Investment Management LLC lifted its holdings in Solid Biosciences by 10.4% during the 4th quarter. MetLife Investment Management LLC now owns 33,202 shares of the company’s stock worth $187,000 after buying an additional 3,124 shares in the last quarter. Quantum Private Wealth LLC grew its stake in shares of Solid Biosciences by 3.9% in the third quarter. Quantum Private Wealth LLC now owns 94,231 shares of the company’s stock worth $581,000 after acquiring an additional 3,500 shares in the last quarter. Legal & General Group Plc increased its position in shares of Solid Biosciences by 208.6% during the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after acquiring an additional 4,063 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Solid Biosciences by 205.5% during the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock worth $33,000 after acquiring an additional 4,534 shares during the period. Finally, Intech Investment Management LLC raised its stake in shares of Solid Biosciences by 15.2% in the fourth quarter. Intech Investment Management LLC now owns 34,485 shares of the company’s stock valued at $194,000 after acquiring an additional 4,539 shares in the last quarter. 81.46% of the stock is owned by hedge funds and other institutional investors.

Solid Biosciences Price Performance

The firm has a market capitalization of $603.57 million, a price-to-earnings ratio of -3.84 and a beta of 2.65. The firm has a 50 day moving average price of $6.53 and a 200-day moving average price of $5.82.

Solid Biosciences (NASDAQ:SLDB) last released its earnings results on Thursday, March 19th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.01. Equities research analysts predict that Solid Biosciences Inc. will post -2.84 earnings per share for the current year.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.